LABORATOIRES THEA
🇫🇷France
- Country
- 🇫🇷France
- Ownership
- -
- Established
- 1994-01-01
- Employees
- -
- Market Cap
- -
Clinical Trials
60
Active:2
Completed:46
Trial Phases
5 Phases
Phase 1:11
Phase 2:10
Phase 3:14
+2 more phases
Drug Approvals
45
CIMA_AEMPS:37
CANADA:4
Drug Approvals
MONOPROST 50 MICROGRAMOS/ML COLIRIO EN SOLUCION EN ENVASE UNIDOSIS
- Approval Date
- Jul 14, 2025
CIMA_AEMPS
- Prev
- 1
- 2
- 3
- 4
- Next
Clinical Trials
Distribution across different clinical trial phases (56 trials with phase data)• Click on a phase to view related trials
Not Applicable
14 (25.0%)Phase 3
14 (25.0%)Phase 1
11 (19.6%)Phase 2
10 (17.9%)Phase 4
7 (12.5%)Real-world Study to Assess Adherence to IOP Lowering Therapy in Glaucoma Patients Using CONNECTDROP®
Recruiting
- Conditions
- Adherence to Glaucoma Therapy
- First Posted Date
- 2025-10-03
- Last Posted Date
- 2025-10-03
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 200
- Registration Number
- NCT07206628
- Locations
- 🇮🇹
Besomed SRLS, Bari, Italy
🇮🇹Studio Oculistico D'Azeglio, Bologna, Italy
🇮🇹Centro Medico Polispecialistico Di Maita, Catania, Italy
A Study to Compare the Effectiveness and Safety of T1695 Versus Ciclosporin in Participants With Moderate to Severe Vernal Keratoconjunctivitis
Not Applicable
Not yet recruiting
- Conditions
- Moderate to Severe Vernal Keratoconjunctivitis
- Interventions
- Diagnostic Test: Slit Lamp ExaminationDiagnostic Test: Far Best Corrected Visual Acuity (BCVA)Drug: T1695Diagnostic Test: Corneal fluorescein staining score on modified Oxford scale
- First Posted Date
- 2025-09-12
- Last Posted Date
- 2025-09-12
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 120
- Registration Number
- NCT07169695
Anti-inflammatory Effects and Clinical Efficacy of Topical Thealoz Total Eye Drops in Patients With Chronic Dry Eye Disease
Completed
- Conditions
- Dry Eye Disease (DED)
- First Posted Date
- 2025-06-06
- Last Posted Date
- 2025-09-25
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 30
- Registration Number
- NCT07007702
- Locations
- 🇦🇹
Universitätsklinik für Klinische Pharmakologie, Allgemeines Krankenhaus Wien, Vienna, Austria
New Preservative-free Combination of Trehalose, Sodium Hyaluronate and N-acetyl-aspartyl-glutamate (NAAGA) in Dry Eye
Phase 4
Not yet recruiting
- Conditions
- Dry Eye Disease (DED)
- First Posted Date
- 2025-04-01
- Last Posted Date
- 2025-04-25
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 30
- Registration Number
- NCT06903741
Study to Evaluate Sepofarsen in Subjects With Leber Congenital Amaurosis (LCA) Type 10 (HYPERION)
Phase 3
Recruiting
- Conditions
- Leber Congenital Amaurosis 10Sensation DisordersEye DiseasesBlindnessEye Disorders CongenitalLeber Congenital AmaurosisNeurological ManifestationsEye Diseases, HereditaryVision DisorderRetinal Disease
- Interventions
- Other: Placebo IVT
- First Posted Date
- 2025-03-24
- Last Posted Date
- 2025-10-09
- Lead Sponsor
- Laboratoires Thea
- Target Recruit Count
- 32
- Registration Number
- NCT06891443
- Locations
- 🇺🇸
UCSF Wayne and Gladys Valley Center for Vision, San Francisco, California, United States
🇺🇸University of Miami - Bascom Palmer Eye Institute, Miami, Florida, United States
🇺🇸University of Iowa, Iowa City, Iowa, United States
- Prev
- 1
- 2
- 3
- 4
- 5
- 12
- Next
News
Emerging Therapies Offer Hope for Usher Syndrome Patients
The Usher Syndrome market is poised for growth with emerging therapies addressing the root cause of the disease, offering alternatives to supportive care.